Get the latest news, insights, and market updates on PRAX (Praxis Precision Medicines, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best 52-week high stocks to buy right now. Piper Sandler on December 5 reaffirmed its Overweight rating and $450 target on Praxis Precision Medicines (NASDAQ:PRAX) after two key regulatory wins. The company’s pre-NDA meeting with the FDA confirmed its ulixacaltamide data package for Essential Tremor is […] Dec 9, 2025 - $PRAX
High Growth Tech Stocks to Watch in US December 2025
As the U.S. stock market navigates a week marked by anticipation of the Federal Reserve's interest rate decision, major indices such as the S&P 500 have recently pulled back from record highs, reflecting investor caution amidst economic uncertainty. In this context, identifying high-growth tech stocks requires a focus on companies with robust innovation strategies and adaptability to changing market dynamics, which can potentially thrive even in volatile environments. Dec 9, 2025 - $PRAX
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p ≤ 0.002) Patients in the RADIANT study of vormatrigine showed rapid, consistent and durable improvement in seizure reduction, reaching 100% for patients continuing through 16 weeks Expansion of the Praxis Analysis of Concordance Framework to include DEEs Showcase of th Dec 8, 2025 - $PRAX
Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone
Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting for ulixacaltamide setting up a planned 2026 filing. See our latest analysis for Praxis Precision Medicines. The stock has gone into overdrive this year, with a 90 day share price return of 429.33% and a 1 year total shareholder return of 255.03%, signaling powerful momentum behind these clinical wins despite a much weaker 5... Dec 6, 2025 - $PRAX
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal. Dec 5, 2025 - $PRAX
Top Midday Gainers
Praxis Precision Medicines (PRAX) reported positive trial results late Thursday of relutrigine to tr Dec 5, 2025 - $PRAX
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story
Praxis Precision Medicines reported that its EMBOLD trial of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies was stopped early for efficacy, while also confirming FDA alignment to submit an ulixacaltamide New Drug Application for essential tremor in early 2026. Together, these updates highlight Praxis’s effort to advance first-in-class neurology therapies across both ultra-rare pediatric epilepsies and a large, under-treated essential tremor population. We’ll now... Dec 5, 2025 - $PRAX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple